Neuland Laboratories Limited
NSE:NEULANDLAB.NS
12710.7 (INR) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 15,585.805 | 11,911.98 | 9,253.03 | 9,242.652 | 7,577.482 | 6,459.802 | 5,127.69 | 5,727.421 | 5,099.701 | 4,647.035 | 4,656.933 | 4,605.86 | 4,485.03 | 3,936.9 | 2,784.21 | 3,067.22 |
Cost of Revenue
| 10,505.593 | 6,137.853 | 5,535.02 | 5,586.983 | 4,777.947 | 4,431.563 | 3,198.611 | 3,259.333 | 3,159.582 | 2,996.211 | 2,949.926 | 3,174.54 | 3,231.88 | 3,129.91 | 2,177.45 | 2,460.15 |
Gross Profit
| 5,080.212 | 5,774.127 | 3,718.01 | 3,655.669 | 2,799.535 | 2,028.239 | 1,929.079 | 2,468.088 | 1,940.119 | 1,650.824 | 1,707.007 | 1,431.32 | 1,253.15 | 806.99 | 606.76 | 607.07 |
Gross Profit Ratio
| 0.326 | 0.485 | 0.402 | 0.396 | 0.369 | 0.314 | 0.376 | 0.431 | 0.38 | 0.355 | 0.367 | 0.311 | 0.279 | 0.205 | 0.218 | 0.198 |
Reseach & Development Expenses
| 435 | 277.576 | 277.23 | 210.658 | 174.114 | 166.321 | 140.507 | 119.522 | 109.517 | 82.422 | 108.262 | 90.257 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 309.172 | 262.924 | 156.926 | 134.892 | 147.982 | 126.719 | 178.752 | 104.625 | 95.038 | 563.084 | 34.26 | 24.292 | 0 | 362.37 | 367.03 | 348.95 |
Selling & Marketing Expenses
| 339.358 | 295.793 | 274.019 | 204.833 | 119.913 | 118.093 | 81.51 | 57.328 | 115.728 | 81.453 | 265.705 | 135.118 | 0 | 0 | 0 | 0 |
SG&A
| 1,051.316 | 558.717 | 430.945 | 339.725 | 267.895 | 244.812 | 260.262 | 104.625 | 95.038 | 644.537 | 814.562 | 702.346 | 0 | 362.37 | 367.03 | 348.95 |
Other Expenses
| 125.443 | 97.482 | 10.818 | 13.351 | 13.332 | 9.96 | 37.457 | 1,654.31 | 1,195.217 | 23.479 | 23.16 | 7.72 | 922.67 | 120.72 | 101.44 | 36.04 |
Operating Expenses
| 1,051.316 | 3,583.474 | 2,763.099 | 2,559.895 | 2,076.698 | 1,649.982 | 1,639.015 | 1,758.935 | 1,290.255 | 1,161.309 | 1,156.519 | 989.43 | 922.67 | 483.09 | 468.47 | 384.99 |
Operating Income
| 4,028.896 | 2,305.566 | 960.903 | 1,096.333 | 735.987 | 384.476 | 290.064 | 709.153 | 649.864 | 489.515 | 550.488 | 441.89 | 330.48 | 323.9 | 138.29 | 222.08 |
Operating Income Ratio
| 0.258 | 0.194 | 0.104 | 0.119 | 0.097 | 0.06 | 0.057 | 0.124 | 0.127 | 0.105 | 0.118 | 0.096 | 0.074 | 0.082 | 0.05 | 0.072 |
Total Other Income Expenses Net
| -14.531 | -148.102 | -139.278 | -42.998 | -206.762 | -181.103 | -150.72 | -214.969 | -229.835 | -242.297 | -204.953 | -252.65 | -322.17 | -274.52 | -236.43 | -75.95 |
Income Before Tax
| 4,014.365 | 2,157.464 | 821.625 | 1,053.335 | 529.225 | 203.373 | 139.344 | 494.184 | 420.029 | 247.218 | 345.535 | 189.24 | 8.31 | 49.38 | -98.14 | 146.13 |
Income Before Tax Ratio
| 0.258 | 0.181 | 0.089 | 0.114 | 0.07 | 0.031 | 0.027 | 0.086 | 0.082 | 0.053 | 0.074 | 0.041 | 0.002 | 0.013 | -0.035 | 0.048 |
Income Tax Expense
| 1,013.576 | 522.288 | 183.405 | 247.028 | 367.12 | 38.957 | 18.715 | 166.154 | 149.235 | 87.897 | 77.997 | 28.08 | -17.39 | -3.3 | -28.93 | 26.93 |
Net Income
| 3,000.789 | 1,635.176 | 638.22 | 806.307 | 162.105 | 164.416 | 120.629 | 328.03 | 273.245 | 159.469 | 268.073 | 138.63 | 25.61 | 52.89 | -69.05 | 119.23 |
Net Income Ratio
| 0.193 | 0.137 | 0.069 | 0.087 | 0.021 | 0.025 | 0.024 | 0.057 | 0.054 | 0.034 | 0.058 | 0.03 | 0.006 | 0.013 | -0.025 | 0.039 |
EPS
| 233.89 | 127.45 | 49.74 | 62.85 | 12.64 | 13.06 | 10.81 | 42.01 | 30.76 | 18.67 | 33.84 | 17.33 | 4.05 | 8.06 | -10.57 | 18.24 |
EPS Diluted
| 233.89 | 127.45 | 49.74 | 62.85 | 12.64 | 13.06 | 10.81 | 42.01 | 30.75 | 18.66 | 33.83 | 17.31 | 4.04 | 8.05 | -10.57 | 18.21 |
EBITDA
| 4,625.895 | 2,815.909 | 1,425.443 | 1,571.098 | 999.652 | 562.423 | 492.627 | 827.299 | 734.272 | 583.687 | 699.874 | 577.89 | 479.39 | 478.01 | 261.92 | 295.78 |
EBITDA Ratio
| 0.297 | 0.236 | 0.154 | 0.17 | 0.132 | 0.087 | 0.096 | 0.144 | 0.144 | 0.126 | 0.15 | 0.125 | 0.107 | 0.121 | 0.094 | 0.096 |